Total Payments
$316,933
2024 Payments
$74,968
Companies
17
Transactions
330
Medicare Patients
852
Medicare Billing
$139,368
Payment Breakdown by Category
Consulting$147,366 (46.5%)
Other$136,734 (43.1%)
Travel$26,005 (8.2%)
Food & Beverage$5,876 (1.9%)
Research$638.62 (0.2%)
Education$247.35 (0.1%)
Gifts$66.00 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $147,366 | 68 | 46.5% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $88,860 | 32 | 28.0% |
| Honoraria | $47,874 | 16 | 15.1% |
| Travel and Lodging | $26,005 | 103 | 8.2% |
| Food and Beverage | $5,876 | 101 | 1.9% |
| Unspecified | $638.62 | 1 | 0.2% |
| Education | $247.35 | 7 | 0.1% |
| Gift | $66.00 | 2 | 0.0% |
Payments by Type
General
$316,295
329 transactions
Research
$638.62
1 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| ARGENX US, INC. | $127,831 | 125 | $0 (2024) |
| MITSUBISHI TANABE PHARMA AMERICA, INC. | $65,369 | 80 | $0 (2024) |
| Amylyx Pharmaceuticals, Inc. | $36,081 | 31 | $0 (2024) |
| Strongbridge US INC. | $33,786 | 42 | $0 (2019) |
| Catalyst Pharmaceuticals, Inc. | $26,734 | 14 | $0 (2023) |
| Alexion Pharmaceuticals, Inc. | $9,494 | 8 | $0 (2024) |
| Genentech USA, Inc. | $9,005 | 9 | $0 (2024) |
| Biogen, Inc. | $6,044 | 8 | $0 (2024) |
| CSL Behring | $1,950 | 1 | $0 (2021) |
| UCB, Inc. | $249.16 | 3 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $74,968 | 68 | ARGENX US, INC. ($50,630) |
| 2023 | $77,563 | 81 | ARGENX US, INC. ($40,928) |
| 2022 | $51,915 | 47 | ARGENX US, INC. ($36,274) |
| 2021 | $32,429 | 30 | MITSUBISHI TANABE PHARMA AMERICA, INC. ($15,950) |
| 2020 | $13,100 | 5 | CATALYST PHARMACEUTICALS, INC. ($12,000) |
| 2019 | $41,765 | 58 | Strongbridge US INC. ($29,908) |
| 2018 | $16,408 | 28 | Mitsubishi Tanabe Pharma America, Inc. ($12,995) |
| 2017 | $8,784 | 13 | Mitsubishi Tanabe Pharma America, Inc. ($5,042) |
All Payment Transactions
330 individual payment records from CMS Open Payments — Page 1 of 14
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 10/04/2024 | ARGENX US, INC. | VYVGART HYTRULO (Drug) | Consulting Fee | Cash or cash equivalent | $5,000.00 | General |
| Category: Neurology | ||||||
| 10/04/2024 | ARGENX US, INC. | VYVGART HYTRULO (Drug) | Travel and Lodging | In-kind items and services | $134.57 | General |
| Category: Neurology | ||||||
| 10/04/2024 | ARGENX US, INC. | VYVGART HYTRULO (Drug) | Food and Beverage | In-kind items and services | $54.60 | General |
| Category: Neurology | ||||||
| 10/04/2024 | ARGENX US, INC. | VYVGART HYTRULO (Drug) | Travel and Lodging | In-kind items and services | $54.00 | General |
| Category: Neurology | ||||||
| 10/04/2024 | ARGENX US, INC. | VYVGART HYTRULO (Drug) | Travel and Lodging | In-kind items and services | $37.60 | General |
| Category: Neurology | ||||||
| 10/04/2024 | ARGENX US, INC. | VYVGART HYTRULO (Drug) | Travel and Lodging | In-kind items and services | $21.21 | General |
| Category: Neurology | ||||||
| 10/04/2024 | ARGENX US, INC. | VYVGART HYTRULO (Drug) | Travel and Lodging | In-kind items and services | $21.08 | General |
| Category: Neurology | ||||||
| 10/02/2024 | ARGENX US, INC. | VYVGART HYTRULO (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $7,500.00 | General |
| Category: Neurology | ||||||
| 10/02/2024 | ARGENX US, INC. | VYVGART HYTRULO (Drug) | Travel and Lodging | Cash or cash equivalent | $420.22 | General |
| Category: Neurology | ||||||
| 10/02/2024 | ARGENX US, INC. | VYVGART HYTRULO (Drug) | Food and Beverage | In-kind items and services | $13.55 | General |
| Category: Neurology | ||||||
| 09/26/2024 | ARGENX US, INC. | VYVGART (Drug) | Consulting Fee | Cash or cash equivalent | $625.00 | General |
| Category: Immunology | ||||||
| 09/21/2024 | ARGENX US, INC. | VYVGART (Drug) | Travel and Lodging | In-kind items and services | $466.95 | General |
| Category: Immunology | ||||||
| 09/21/2024 | ARGENX US, INC. | VYVGART (Drug) | Travel and Lodging | In-kind items and services | $363.21 | General |
| Category: Immunology | ||||||
| 09/21/2024 | ARGENX US, INC. | VYVGART (Drug) | Travel and Lodging | In-kind items and services | $140.00 | General |
| Category: Immunology | ||||||
| 09/21/2024 | ARGENX US, INC. | VYVGART (Drug) | Travel and Lodging | In-kind items and services | $50.00 | General |
| Category: Immunology | ||||||
| 09/12/2024 | ARGENX US, INC. | — | Consulting Fee | Cash or cash equivalent | $937.50 | General |
| 08/23/2024 | ARGENX US, INC. | VYVGART HYTRULO (Drug) | Food and Beverage | In-kind items and services | $120.06 | General |
| Category: Neurology | ||||||
| 08/23/2024 | ARGENX US, INC. | VYVGART HYTRULO (Drug) | Food and Beverage | In-kind items and services | $24.23 | General |
| Category: Neurology | ||||||
| 08/10/2024 | Genentech USA, Inc. | Evrysdi (Drug) | Consulting Fee | Cash or cash equivalent | $6,725.00 | General |
| Category: Neurology | ||||||
| 08/10/2024 | Genentech USA, Inc. | Evrysdi (Drug) | Travel and Lodging | In-kind items and services | $762.06 | General |
| Category: Neurology | ||||||
| 08/10/2024 | Genentech USA, Inc. | Evrysdi (Drug) | Travel and Lodging | In-kind items and services | $649.06 | General |
| Category: Neurology | ||||||
| 08/10/2024 | Genentech USA, Inc. | Evrysdi (Drug) | Food and Beverage | In-kind items and services | $219.38 | General |
| Category: Neurology | ||||||
| 08/10/2024 | Genentech USA, Inc. | Evrysdi (Drug) | Travel and Lodging | Cash or cash equivalent | $217.62 | General |
| Category: Neurology | ||||||
| 08/10/2024 | Genentech USA, Inc. | Evrysdi (Drug) | Food and Beverage | In-kind items and services | $168.76 | General |
| Category: Neurology | ||||||
| 08/10/2024 | Genentech USA, Inc. | Evrysdi (Drug) | Food and Beverage | In-kind items and services | $128.25 | General |
| Category: Neurology | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of BIIB100 Administered Orally to Adults With Amyotrophic Lateral Sclerosis | Biogen, Inc. | $638.62 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 4 | 176 | 268 | $107,905 | $32,085 |
| 2022 | 5 | 166 | 240 | $97,635 | $29,817 |
| 2021 | 8 | 248 | 352 | $134,580 | $43,831 |
| 2020 | 8 | 262 | 349 | $117,895 | $33,635 |
Total Patients
852
Total Services
1,209
Medicare Billing
$139,368
Procedure Codes
25
All Medicare Procedures & Services
25 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 104 | 179 | $76,075 | $23,500 | 30.9% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2023 | 26 | 26 | $15,730 | $3,810 | 24.2% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 28 | 34 | $10,880 | $3,295 | 30.3% |
| 95885 | Needle measurement of electrical activity in arm or leg muscles, limited study | Office | 2023 | 18 | 29 | $5,220 | $1,481 | 28.4% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2022 | 89 | 154 | $65,450 | $20,646 | 31.5% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 33 | 39 | $12,480 | $3,535 | 28.3% |
| 95913 | Nerve conduction, 13 or more studies | Office | 2022 | 11 | 11 | $7,700 | $2,538 | 33.0% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2022 | 13 | 13 | $7,865 | $1,840 | 23.4% |
| 95885 | Needle measurement of electrical activity in arm or leg muscles, limited study | Office | 2022 | 20 | 23 | $4,140 | $1,258 | 30.4% |
| 99215 | Established patient outpatient visit, total time 40-54 minutes | Office | 2021 | 84 | 155 | $65,875 | $22,539 | 34.2% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 38 | 46 | $14,720 | $4,877 | 33.1% |
| 95913 | Nerve transmission studies, 13 or more studies | Office | 2021 | 18 | 19 | $13,300 | $4,324 | 32.5% |
| 99205 | New patient outpatient visit, total time 60-74 minutes | Office | 2021 | 23 | 23 | $13,915 | $4,127 | 29.7% |
| 99204 | New patient outpatient visit, total time 45-59 minutes | Office | 2021 | 23 | 23 | $11,155 | $3,294 | 29.5% |
| 95885 | Needle measurement and recording of electrical activity of muscles of arm or leg limited study | Office | 2021 | 31 | 50 | $9,000 | $2,924 | 32.5% |
| 99222 | Initial hospital inpatient care, typically 50 minutes per day | Facility | 2021 | 14 | 15 | $6,000 | $1,596 | 26.6% |
| 94010 | Measurement and graphic recording of total and timed exhaled air capacity | Office | 2021 | 17 | 21 | $615.00 | $151.88 | 24.7% |
| 99215 | Established patient office or other outpatient, visit typically 40 minutes | Office | 2020 | 64 | 94 | $39,950 | $10,369 | 26.0% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Office | 2020 | 72 | 104 | $33,280 | $9,075 | 27.3% |
| 95913 | Nerve transmission studies, 13 or more studies | Office | 2020 | 17 | 17 | $11,900 | $4,303 | 36.2% |
| 99205 | New patient office or other outpatient visit, typically 60 minutes | Office | 2020 | 16 | 16 | $9,680 | $2,815 | 29.1% |
| 99204 | New patient office or other outpatient visit, typically 45 minutes | Office | 2020 | 23 | 23 | $11,155 | $2,798 | 25.1% |
| 95885 | Needle measurement and recording of electrical activity of muscles of arm or leg limited study | Office | 2020 | 31 | 43 | $7,740 | $2,221 | 28.7% |
| 99443 | Physician telephone patient service, 21-30 minutes of medical discussion | Office | 2020 | 14 | 20 | $3,300 | $1,821 | 55.2% |
| 94010 | Measurement and graphic recording of total and timed exhaled air capacity | Office | 2020 | 25 | 32 | $890.00 | $231.66 | 26.0% |
About Dr. Jeffrey Rosenfeld, MD
Dr. Jeffrey Rosenfeld, MD is a Clinical Neurophysiology healthcare provider based in Fresno, California. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 07/13/2006. The National Provider Identifier (NPI) number assigned to this provider is 1811912348.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Jeffrey Rosenfeld, MD has received a total of $316,933 in payments from pharmaceutical and medical device companies, with $74,968 received in 2024. These payments were reported across 330 transactions from 17 companies. The most common payment nature is "Consulting Fee" ($147,366).
As a Medicare-enrolled provider, Rosenfeld has provided services to 852 Medicare beneficiaries, totaling 1,209 services with total Medicare billing of $139,368. Data is available for 4 years (2020–2023), covering 25 distinct procedure/service records.
Ad
Practice Information
- Specialty Clinical Neurophysiology
- Other Specialties Internal Medicine, Neurology
- Location Fresno, CA
- Active Since 07/13/2006
- Last Updated 06/20/2014
- Taxonomy Code 2084N0600X
- Entity Type Individual
- NPI Number 1811912348
Products in Payments
- VYVGART (Drug) $113,144
- RELYVRIO (Drug) $36,081
- KEVEYIS (Drug) $33,786
- Radicava (Drug) $30,544
- FIRDAPSE (Drug) $26,734
- RADICAVA (Drug) $24,094
- VYVGART HYTRULO (Drug) $13,750
- Evrysdi (Drug) $9,068
- Radicava ORS (Drug) $5,500
- ULTOMIRIS (Biological) $4,278
- EXSERVAN (Drug) $3,850
- Soliris (Drug) $2,040
- Hizentra (Biological) $1,950
- SPINRAZA (Biological) $461.39
- DISEASE STATE (Drug) $100.73
- EMFLAZA (Drug) $78.96
- LIORESAL (BACLOFEN) (Drug) $66.00
- Hillrom - Vest System Model 105 Home Care (Device) $44.10
- SOLIRIS (Drug) $34.68
- Gamunex-C (Biological) $23.25
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.